Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.1.45

Roles of MiR-101 and its Target Gene Cox-2 in Early Diagnosis of Cervical Cancer in Uygur Women  

Lin, Chen (Department of Pathology, College of Basic Medicine, Xinjiang Medical University)
Huang, Fei (Department of Pathology, College of Basic Medicine, Xinjiang Medical University)
Zhang, Ya-Jing (Department of Pathology, The Forth Affiliated Hospital, Xinjiang Medical University)
Tuokan, Talafu (Department of Pathology, College of Basic Medicine, Xinjiang Medical University)
Kuerban, Gulinaer (Department of Pathology, College of Basic Medicine, Xinjiang Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.1, 2014 , pp. 45-48 More about this Journal
Abstract
Aims: Early diagnosis is important for cervical cancer treatment. This study aimed to characteriz the microRNA profile and target gene protein levels of cervical cancers in Uygur women for application in early diagnosis. Methods: The profiles of miRNA in cervical cancer and chronic cervicitis were analyzed with miRNAmicroarray V4.0. The expression of miR-101 was detected by real-time PCR and locked nucleotide acid in situ hybridization (LNA-ISH). Cox-2 protein levels were assessed by immunohistochemistry. Results: The microarray identified a set of 12 miRNAs significantly decreased in cervical cancer in comparison to the control group. Quantitative RT-PCR analysis showed miR-101 to be significantly downregulated in cancer tissues (p<0.05) while LNA-ISH showed miR-101 positive rates of 80% (20/25) and 8% (5/25) (p<0.05) in the control and cervical cancer groups. Cox-2 positive rates of cervical cancer and control groups were 84% (21/25) and 8% (2/25) (p<0.05). Conclusions: Use of down-regulation of miR-101 and up-regulation of Cox-2 as markers may play a role in early diagnosis of cervical cancer in Uygur women.
Keywords
MicroRNA; cervical cancer; Uygur ethnicity; miR-101; Cox-2;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hao Y, Gu X, Zhao Y (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the Cox-2 pathway in vivo. Cancer Prev Res, 4, 1073-83.   DOI   ScienceOn
2 Wang HJ, Ruan HJ, He XJ, et al (2010). MicroRNA-101 is downregulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer, 46, 2295-303.   DOI   ScienceOn
3 Wang R, Wang HB, Hao CJ, et al (2012). MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One, 7, e46173.   DOI
4 Wu ZL, Zheng SS, Li ZM, et al (2010). Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ, 17, 801-10.   DOI   ScienceOn
5 Zhang Y, Guo X, Xiong L, et al (2012). MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett, 586, 4362-70.   DOI   ScienceOn
6 Hao Y, Gu X, Zhao Y, et al (2011). Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the Cox-2 pathway in vivo. Cancer Prev Res, 4, 1073-83.   DOI   ScienceOn
7 Cao W, Ribeiro Rde O, Liu D, et al (2012). EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with nonsmall cell lung cancer. PLoS One, 7, e52984.   DOI
8 Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, et al (2012). MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther, 13, 175-83.   DOI
9 Chen J, Yao D, Li Y (2013). Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervicalsquamous cell carcinoma. Int J Mol Med, 32, 557-67.
10 Garzon R, Calin GA, Croce CM (2009). MicroRNAs in Cancer. Annu Rev Med, 60, 167-79.   DOI   ScienceOn
11 Lalaisuzuke, Peng YH, Zhou K, et al (2006). The analysis of pathogenetic tendency of cervical cancer in various ethnic women in Xinjiang. J Xinjiang Med Univ, 29, 569-71.
12 Lee JW, Choi CH, Choi JJ (2008). Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res, 14, 2535-42.   DOI   ScienceOn
13 Pang Y, Young CY, Yuan H (2010). MicroRNAs and prostate cancer. Acta Biochem Biophys Sin, 42, 363-9.   DOI   ScienceOn
14 Rao Q, Shen Q, Zhou H, et al. Aberrant microRNA expression in human cervical carcinomas. Med Oncol, 29, 1242-8.
15 Strillacci A, Valerii MC, Sansone P (2013) Loss of miR-101 expression promotes Wnt/${\beta}$-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol, 229, 379-89.   DOI   ScienceOn
16 Bumgarner SL, Dowell RD, Grisafi P, et al (2009). Toggle involving cis-interfering noncoding RNAs controls variegated gene expreassion in yeast. Proc Natl Acad Sci USA, 106, 18321-6.   DOI   ScienceOn
17 Su H, Yang JR, Xu T, et al (2009). MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69, 1135-42.
18 Arbyn M, Castellsague X, de Sanjose S, et al (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol, 22, 2675-86.   DOI   ScienceOn
19 Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.   DOI   ScienceOn
20 Zhang JG, Guo JF, Liu DL, et al (2011). MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol, 6, 671-8.   DOI   ScienceOn